{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:23:07Z","timestamp":1791361387151,"version":"4.3.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1476-4598-13-152","type":"journal-article","created":{"date-parts":[[2014,6,16]],"date-time":"2014-06-16T18:00:05Z","timestamp":1402941605000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A"],"prefix":"10.1186","volume":"13","author":[{"given":"Eva","family":"Juengel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snigdha","family":"Nowaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmina","family":"Makarevi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iyad","family":"Natsheh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Tsaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Mani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Harder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Haferkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman A","family":"Blaheta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,16]]},"reference":[{"issue":"2","key":"1354_CR1","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante M, Sabatini DM: mTOR signaling in growth control and disease. Cell. 2012, 149 (2): 274-293. 10.1016\/j.cell.2012.03.017","journal-title":"Cell"},{"issue":"9637","key":"1354_CR2","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Gr\u00fcnwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A: RECORD-1 Study Group: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008, 372 (9637): 449-456. 10.1016\/S0140-6736(08)61039-9","journal-title":"Lancet"},{"issue":"18","key":"1354_CR3","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1002\/cncr.25219","volume":"116","author":"RJ Motzer","year":"2010","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Gr\u00fcnwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A: RECORD\u20121 Study Group: Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010, 116 (18): 4256-4265. 10.1002\/cncr.25219","journal-title":"Cancer"},{"issue":"22","key":"1354_CR4","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ: Global ARCC Trial: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007, 356 (22): 2271-2281. 10.1056\/NEJMoa066838","journal-title":"N Engl J Med"},{"issue":"9","key":"1354_CR5","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1038\/bjc.2013.602","volume":"109","author":"K Harada","year":"2013","unstructured":"Harada K, Miyake H, Kumano M, Fujisawa M: Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2. Br J Cancer. 2013, 109 (9): 2389-2395. 10.1038\/bjc.2013.602","journal-title":"Br J Cancer"},{"issue":"1","key":"1354_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.canlet.2012.05.003","volume":"324","author":"E Juengel","year":"2012","unstructured":"Juengel E, Dauselt A, Makarevi\u0107 J, Wiesner C, Tsaur I, Bartsch G, Haferkamp A, Blaheta RA: Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells. Cancer Lett. 2012, 324 (1): 83-90. 10.1016\/j.canlet.2012.05.003","journal-title":"Cancer Lett"},{"issue":"1","key":"1354_CR7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.canlet.2011.08.026","volume":"313","author":"I Tsaur","year":"2011","unstructured":"Tsaur I, Makarevi\u0107 J, Hudak L, Juengel E, Kurosch M, Wiesner C, Bartsch G, Harder S, Haferkamp A, Blaheta RA: The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line. Cancer Lett. 2011, 313 (1): 84-90. 10.1016\/j.canlet.2011.08.026","journal-title":"Cancer Lett"},{"issue":"2","key":"1354_CR8","first-page":"221","volume":"1845","author":"M Santoni","year":"2014","unstructured":"Santoni M, Pantano F, Amantini C, Nabissi M, Conti A, Burattini L, Zoccoli A, Berardi R, Santoni G, Tonini G, Santini D, Cascinu S: Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma. Biochim Biophys Acta. 2014, 1845 (2): 221-231.","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"1354_CR9","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1158\/1078-0432.CCR-12-3909","volume":"20","author":"CH Chen","year":"2014","unstructured":"Chen CH, Chen MC, Wang JC, Tsai AC, Chen CS, Liou JP, Pan SL, Teng CM: Synergistic Interaction between the HDAC Inhibitor, MPT0E028, and Sorafenib in Liver Cancer Cells In Vitro and In Vivo. Clin Cancer Res. 2014, 20 (5): 1274-1287. 10.1158\/1078-0432.CCR-12-3909","journal-title":"Clin Cancer Res"},{"key":"1354_CR10","unstructured":"Hrabeta J, Stiborova M, Adam V, Kizek R, Eckschlager T: Histone deacetylase inhibitors in cancer therapy. A review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. in press,"},{"issue":"12","key":"1354_CR11","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.18632\/oncotarget.1314","volume":"4","author":"L Ellis","year":"2013","unstructured":"Ellis L, Ku SY, Ramakrishnan S, Lasorsa E, Azabdaftari G, Godoy A, Pili R: Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer. Oncotarget. 2013, 4 (12): 2225-2236.","journal-title":"Oncotarget"},{"key":"1354_CR12","doi-asserted-by":"publisher","first-page":"e25192","DOI":"10.1371\/journal.pone.0025192","volume":"6","author":"E de Jong","year":"2011","unstructured":"de Jong E, Winkel P, Poelstra K, Prakash J: Anticancer effects of 15d-prostaglandin-J2 in wild-type and doxorubicin-resistant ovarian cancer cells: novel actions on SIRT1 and HDAC. PLoS One. 2011, 6: e25192- 10.1371\/journal.pone.0025192","journal-title":"PLoS One"},{"key":"1354_CR13","doi-asserted-by":"publisher","first-page":"4412","DOI":"10.1158\/0008-5472.CAN-10-4111","volume":"71","author":"EA Stronach","year":"2011","unstructured":"Stronach EA, Alfraidi A, Rama N, Datler C, Studd JB, Agarwal R, Guney TG, Gourley C, Hennessy BT, Mills GB, Mai A, Brown R, Dina R, Gabra H: HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res. 2011, 71: 4412-4422. 10.1158\/0008-5472.CAN-10-4111","journal-title":"Cancer Res"},{"issue":"11","key":"1354_CR14","doi-asserted-by":"publisher","first-page":"e78398","DOI":"10.1371\/journal.pone.0078398","volume":"8","author":"JT Fong","year":"2013","unstructured":"Fong JT, Jacobs RJ, Moravec DN, Uppada SB, Botting GM, Nlend M, Puri N: Alternative Signaling Pathways as Potential Therapeutic Targets for Overcoming EGFR and c-Met Inhibitor Resistance in Non-Small Cell Lung Cancer. PLoS One. 2013, 8 (11): e78398- 10.1371\/journal.pone.0078398","journal-title":"PLoS One"},{"issue":"2","key":"1354_CR15","doi-asserted-by":"publisher","first-page":"E211","DOI":"10.1111\/j.1464-410X.2012.11655.x","volume":"112","author":"I Sakai","year":"2013","unstructured":"Sakai I, Miyake H, Fujisawa M: Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation. BJU Int. 2013, 112 (2): E211-E220. 10.1111\/j.1464-410X.2012.11655.x","journal-title":"BJU Int"},{"issue":"10","key":"1354_CR16","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.18632\/oncotarget.1246","volume":"4","author":"J Liu","year":"2013","unstructured":"Liu J, Xiao Z, Wong SK, Tin VP, Ho KY, Wang J, Sham MH, Wong MP: Lung cancer tumorigenicity and drug resistance are maintained through ALDH(hi)CD44(hi) tumor initiating cells. Oncotarget. 2013, 4 (10): 1698-1711.","journal-title":"Oncotarget"},{"issue":"6","key":"1354_CR17","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1158\/0008-5472.CAN-13-1729","volume":"74","author":"A Lin","year":"2014","unstructured":"Lin A, Piao HL, Zhuang L, Sarbassov DD, Ma L, Gan B: FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacological inhibition of the PI3K-AKT pathway. Cancer Res. 2014, 74 (6): 1682-1693. 10.1158\/0008-5472.CAN-13-1729","journal-title":"Cancer Res"},{"issue":"1","key":"1354_CR18","doi-asserted-by":"publisher","first-page":"e53100","DOI":"10.1371\/journal.pone.0053100","volume":"8","author":"E Juengel","year":"2013","unstructured":"Juengel E, Makarevi\u0107 J, Tsaur I, Bartsch G, Nelson K, Haferkamp A, Blaheta RA: Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo. PLoS One. 2013, 8 (1): e53100- 10.1371\/journal.pone.0053100","journal-title":"PLoS One"},{"issue":"1","key":"1354_CR19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1476-4598-13-42","volume":"13","author":"E Joeckel","year":"2014","unstructured":"Joeckel E, Haber T, Prawitt D, Junker K, Hampel C, Th\u00fcroff JW, Roos FC, Brenner W: High calcium concentration in bones promotes bone metastasis in renal cell carcinomas expressing calcium-sensing receptor. Mol Cancer. 2014, 13 (1): 42- 10.1186\/1476-4598-13-42","journal-title":"Mol Cancer"},{"issue":"2","key":"1354_CR20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.lfs.2014.02.002","volume":"100","author":"YC Ou","year":"2014","unstructured":"Ou YC, Li JR, Kuan YH, Raung SL, Wang CC, Hung YY, Pan PH, Lu HC, Chen CJ: Luteolin sensitizes human 786-O renal cell carcinoma cells to TRAIL-induced apoptosis. Life Sci. 2014, 100 (2): 110-117. 10.1016\/j.lfs.2014.02.002","journal-title":"Life Sci"},{"issue":"5","key":"1354_CR21","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/bjc.2013.828","volume":"110","author":"NM White","year":"2014","unstructured":"White NM, Masui O, Newsted D, Scorilas A, Romaschin AD, Bjarnason GA, Siu KW, Yousef GM: Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF\/mTOR signaling axis. Br J Cancer. 2014, 110 (5): 1250-1259. 10.1038\/bjc.2013.828","journal-title":"Br J Cancer"},{"issue":"10","key":"1354_CR22","doi-asserted-by":"publisher","first-page":"e76183","DOI":"10.1371\/journal.pone.0076183","volume":"8","author":"J El Andalousi","year":"2013","unstructured":"El Andalousi J, Li Y, Anand-Srivastava MB: Natriuretic peptide receptor-C agonist attenuates the expression of cell cycle proteins and proliferation of vascular smooth muscle cells from spontaneously hypertensive rats: role of Gi proteins and MAPkinase\/PI3kinase signaling. PLoS One. 2013, 8 (10): e76183- 10.1371\/journal.pone.0076183","journal-title":"PLoS One"},{"issue":"3","key":"1354_CR23","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/annonc\/mdt578","volume":"25","author":"MH Voss","year":"2014","unstructured":"Voss MH, Bastos DA, Karlo CA, Ajeti A, Hakimi AA, Feldman DR, Hsieh JJ, Molina AM, Patil S, Motzer RJ: Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies. Ann Oncol. 2014, 25 (3): 663-668. 10.1093\/annonc\/mdt578","journal-title":"Ann Oncol"},{"issue":"3","key":"1354_CR24","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/annonc\/mdt575","volume":"25","author":"M Arnedos","year":"2014","unstructured":"Arnedos M, Drury S, Afentakis M, A'hern R, Hills M, Salter J, Smith IE, Reis-Filho JS, Dowsett M: Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer. Ann Oncol. 2014, 25 (3): 605-610. 10.1093\/annonc\/mdt575","journal-title":"Ann Oncol"},{"issue":"6","key":"1354_CR25","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1038\/bjc.2014.31","volume":"110","author":"S Deb","year":"2014","unstructured":"Deb S, Xu H, Tuynman J, George J, Yan Y, Li J, Ward RL, Mortensen N, Hawkins NJ, McKay MJ, Ramsay RG, Fox SB: RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas. Br J Cancer. 2014, 110 (6): 1606-1613. 10.1038\/bjc.2014.31","journal-title":"Br J Cancer"},{"key":"1354_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fonc.2014.00012","volume":"4","author":"HM Jeong","year":"2014","unstructured":"Jeong HM, Kwon MJ, Shin YK: Overexpression of Cancer-Associated Genes via Epigenetic Derepression Mechanisms in Gynecologic Cancer. Front Oncol. 2014, 4: 12-","journal-title":"Front Oncol"},{"issue":"4","key":"1354_CR27","doi-asserted-by":"publisher","first-page":"979","DOI":"10.3892\/or.2011.1172","volume":"25","author":"J Li","year":"2011","unstructured":"Li J, Zhu W, Leng T, Shu M, Huang Y, Xu D, Qiu P, Su X, Yan G: Triptolide-induced cell cycle arrest and apoptosis in human renal cell carcinoma cells. Oncol Rep. 2011, 25 (4): 979-987.","journal-title":"Oncol Rep"},{"issue":"12","key":"1354_CR28","doi-asserted-by":"publisher","first-page":"e81902","DOI":"10.1371\/journal.pone.0081902","volume":"8","author":"M Klintman","year":"2013","unstructured":"Klintman M, Strand C, Ahlin C, Beglerbegovic S, Fj\u00e4llskog ML, Grabau D, Gudlaugsson E, Janssen EA, L\u00f6vgren K, Skaland I, Bendahl PO, Malmstr\u00f6m P, Baak JP, Fern\u00f6 M: The Prognostic Value of Mitotic Activity Index (MAI), Phosphohistone H3 (PPH3), Cyclin B1, Cyclin A, and Ki67, Alone and in Combinations, in Node-Negative Premenopausal Breast Cancer. PLoS One. 2013, 8 (12): e81902- 10.1371\/journal.pone.0081902","journal-title":"PLoS One"},{"issue":"1","key":"1354_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10549-011-1386-5","volume":"131","author":"C Strand","year":"2012","unstructured":"Strand C, Ahlin C, Bendahl PO, Fj\u00e4llskog ML, Hedenfalk I, Malmstr\u00f6m P, Fern\u00f6 M: Combination of the proliferation marker cyclin A, histological grade, and estrogen receptor status in a new variable with high prognostic impact in breast cancer. Breast Cancer Res Treat. 2012, 131 (1): 33-40. 10.1007\/s10549-011-1386-5","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"1354_CR30","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1158\/1055-9965.EPI-09-0169","volume":"18","author":"C Ahlin","year":"2009","unstructured":"Ahlin C, Zhou W, Holmqvist M, Holmberg L, Nilsson C, Jirstr\u00f6m K, Blomqvist C, Amini RM, Fj\u00e4llskog ML: Cyclin A is a proliferative marker with good prognostic value in node-negative breast cancer. Cancer Epidemiol Biomarkers Prev. 2009, 18 (9): 2501-2506. 10.1158\/1055-9965.EPI-09-0169","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"1354_CR31","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/cncr.10338","volume":"94","author":"T Migita","year":"2002","unstructured":"Migita T, Oda Y, Naito S, Tsuneyoshi M: Low expression of p27(Kip1) is associated with tumor size and poor prognosis in patients with renal cell carcinoma. Cancer. 2002, 94 (4): 973-979. 10.1002\/cncr.10338","journal-title":"Cancer"},{"key":"1354_CR32","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1038\/sj.bjc.6603777","volume":"96","author":"RA Blaheta","year":"2007","unstructured":"Blaheta RA, Michaelis M, Natsheh I, Hasenberg C, Weich E, Relja B, Jonas D, Doerr HW, Cinatl J: Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium. Br J Cancer. 2007, 96: 1699-1706. 10.1038\/sj.bjc.6603777","journal-title":"Br J Cancer"},{"key":"1354_CR33","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1097\/CAD.0b013e32834a2c70","volume":"22","author":"S Vallo","year":"2011","unstructured":"Vallo S, Xi W, Hudak L, Juengel E, Tsaur I, Wiesner C, Haferkamp A, Blaheta RA: HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro. Anticancer Drugs. 2011, 22: 1002-1009.","journal-title":"Anticancer Drugs"},{"key":"1354_CR34","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1186\/1471-2407-11-375","volume":"11","author":"S Wedel","year":"2011","unstructured":"Wedel S, Hudak L, Seibel JM, Makarevi\u0107 J, Juengel E, Tsaur I, Waaga-Gasser A, Haferkamp A, Blaheta RA: Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis. BMC Cancer. 2011, 11: 375- 10.1186\/1471-2407-11-375","journal-title":"BMC Cancer"},{"key":"1354_CR35","unstructured":"Kumar P, Tripathi S, Pandey KN: Histone Deacetylase Inhibitors Modulate the Transcriptional Regulation of Guanylyl Cyclase\/Natriuretic Peptide Receptor-A Gene: Interactive roles of Modified Histones, HATS, p300, and Sp1. J Biol Chem. in press,"},{"key":"1354_CR36","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1111\/j.1582-4934.2008.00436.x","volume":"13","author":"J Jones","year":"2009","unstructured":"Jones J, Juengel E, Mickuckyte A, Hudak L, Wedel S, Jonas D, Blaheta RA: The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo. J Cell Mol Med. 2009, 13: 2376-2385. 10.1111\/j.1582-4934.2008.00436.x","journal-title":"J Cell Mol Med"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-4598-13-152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T04:31:13Z","timestamp":1630557073000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/1476-4598-13-152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,16]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1354"],"URL":"https:\/\/doi.org\/10.1186\/1476-4598-13-152","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,16]]},"assertion":[{"value":"8 April 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"152"}}